FOSUN PHARMA (02196) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.5% YoY to RMB2.52 Billion

Stock News

10/28

FOSUN PHARMA (02196) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB29.39 billion, representing a year-on-year decrease of 4.91%. Net profit attributable to shareholders of the listed company reached RMB2.52 billion, up 25.5% compared to the same period last year. Basic earnings per share stood at RMB0.95.

The year-on-year decline in revenue for both the first three quarters of 2025 and the reporting period (July–September) was primarily due to the impact of volume-based procurement renewals and regional centralized drug procurement initiatives. However, revenue from innovative drugs maintained steady growth during the same period.

The increase in total profit, net profit attributable to shareholders, and basic and diluted earnings per share for the first three quarters of 2025 was mainly driven by gains from the disposal of remaining equity in United Family Healthcare and other non-core assets.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1179075043"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179075043\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179075043?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179075043","market":"hk","top_or_hot":-1,"title":"FOSUN PHARMA (02196) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.5% YoY to RMB2.52 Billion","media":"Stock News","content":"<p>FOSUN PHARMA (02196) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB29.39 billion, representing a year-on-year decrease of 4.91%. Net profit attributable to shareholders of the listed company reached RMB2.52 billion, up 25.5% compared to the same period last year. Basic earnings per share stood at RMB0.95.</p>\n<p>The year-on-year decline in revenue for both the first three quarters of 2025 and the reporting period (July–September) was primarily due to the impact of volume-based procurement renewals and regional centralized drug procurement initiatives. However, revenue from innovative drugs maintained steady growth during the same period.</p>\n<p>The increase in total profit, net profit attributable to shareholders, and basic and diluted earnings per share for the first three quarters of 2025 was mainly driven by gains from the disposal of remaining equity in United Family Healthcare and other non-core assets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA (02196) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.5% YoY to RMB2.52 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA (02196) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.5% YoY to RMB2.52 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-28 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB29.39 billion, representing a year-on-year decrease of 4.91%. Net profit attributable to shareholders of the listed company reached RMB2.52 billion, up 25.5% compared to the same period last year. Basic earnings per share stood at RMB0.95.</p>\n<p>The year-on-year decline in revenue for both the first three quarters of 2025 and the reporting period (July–September) was primarily due to the impact of volume-based procurement renewals and regional centralized drug procurement initiatives. However, revenue from innovative drugs maintained steady growth during the same period.</p>\n<p>The increase in total profit, net profit attributable to shareholders, and basic and diluted earnings per share for the first three quarters of 2025 was mainly driven by gains from the disposal of remaining equity in United Family Healthcare and other non-core assets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0187","symbol_name":"一线龙头","start_time":0,"source_url":"","article_id":"1179075043","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179075043","pubTimestamp":1761642854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB29.39 billion, representing a year-on-year decrease of 4.91%. Net...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0187":"一线龙头","BK0060":"抗癌","BK0175":"白马股","BK0028":"国家队","BK0239":"医药制造","02196":"复星医药","BK0012":"证金概念","BK0183":"MSCI概念","BK1515":"抗疫概念","BK0096":"民营医院","BK0188":"融资融券","BK1191":"制药","BK1593":"医美概念股","BK0196":"行业龙头"},"translate_title":"复星医药(02196)公布第三季度业绩：归属股东净利润同比增长25.5%至人民币25.2亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (02196) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB29.39 billion, representing a year-on-year decrease of 4.91%. Net profit attributable to shareholders of the listed company reached RMB2.52 billion, up 25.5% compared to the same period last year. Basic earnings per share stood at RMB0.95.\nThe year-on-year decline in revenue for both the first three quarters of 2025 and the reporting period (July–September) was primarily due to the impact of volume-based procurement renewals and regional centralized drug procurement initiatives. However, revenue from innovative drugs maintained steady growth during the same period.\nThe increase in total profit, net profit attributable to shareholders, and basic and diluted earnings per share for the first three quarters of 2025 was mainly driven by gains from the disposal of remaining equity in United Family Healthcare and other non-core assets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}